Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | April 08, 2014

Key News and Technology at ACC.14

By Dave Fornell

The biggest news item from the American College of Cardiology (ACC) 63rd Annual Scientific Session was that a transcatheter aortic valve had 26 percent better survival in high-risk patients than surgical valve replacement. This is a big deal, as it shows the promise of transcatheter valve technology to eventually replace open-heart surgical procedures is not a theory out in left field. What is more impressive is the fact that the operators were given three patients to learn how to use the CoreValve device before their fourth and subsequent patients counted in the trial. Despite the relative inexperience with the device and procedure compared to cardiac surgeons, who in most cases have been performing valve replacements for a decade or longer, the fact that the new device outperformed surgery is very impressive. Read more on the trial or watch a video interview with one of the lead investigators.

The major disappointment at ACC.14 was the presentation of the SYMPLICITY HTN-3 renal denervation U.S. pivotal trial. The device used failed to reduce blood pressure a statistically significant amount over a sham procedure, calling into question the future of denervation technology. This session was packed solid with thousands of attendees, who wanted to hear the details and what the future might be for this technology. Read more on the trial or watch a video interview with one of the investigators.

A key late-breaking presentation for cardiac imaging was a combination of five trials that show coronary artery calcium scoring provides an early indication of a patient’s long-term risk for heart disease. Read more on the trial.

A key presentation in electrophysiology was the long-term results from the MADIT-CRT trial, which showed greatly improved outcomes and survival in heart failure patients with left bundle branch block. Read more on the trial.

I walked the exposition show floor and found several new, innovative technologies and on display. I also found some technologies that highlight trends in cardiology, including examples of how to achieve patient engagement and enterprise imaging. Watch the video “DAIC Editor’s Choice for Most Innovative New Technology.”

Related Content

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement
News | Heart Failure | November 02, 2018
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the...
Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

News | Heart Failure | November 01, 2018
November 1, 2018 — Daxor Corp.
NHLBI Pauses CONCERT-HF Heart Failure Trial
News | Heart Failure | October 29, 2018
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is pausing the...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Cardiac Dimensions Randomizes First Patient in CARILLON Trial of Mitral Contour System
News | Heart Failure | September 20, 2018
Cardiac Dimensions announced the company has randomized its first patient in the CARILLON Pivotal Trial.
Overlay Init